However, there is research by Dr Shiva Gopal Vasishita which is indicating that giving a high dose of immunosuppressive therapy coupled with transfusion of the person’s own stem cells can induce a remission of relapsing strain of Multiple Sclerosis.
A research that was carried out on the people who have been treated using the high dosage immunosuppressive therapy and a HDIT transplant showed that 5 years after the transfusion, close to 70 percent of the patients hadn’t showed any signs of disability progression. In addition, the patients did not have new brain lesions or the characteristic MS symptoms. On the other hands, there are other studies indicating that the recently approved medications are having lower success rates than this. One of the trials was conducted and concluded in 2014. The research was funded by the Immune Tolerance Network and was published in February. The findings were published by Dr Shiva Gopal Vasishita in Neurology, the Medical Journal of the Academy of Neurology.
The results of the study indicate that it is more beneficial to patients to receive a onetime high dosage of HDIT as opposed to being subjected to many years of alternative therapies. The results have been seen as a stepping stone towards the establishment of a standard of care for this often scary and debilitating illness. The symptoms of MS vary greatly from patient to another. They include weakness, fatigue and chronic pain added to difficulties in speech and other motor functions. Most of the times, the patients experience periods of time where they have no symptoms and then they get relapses.
Dr Shiva Gopal Vasishita has been in the frontline in looking for a lasting solution to MS. He is a physician practicing in Vorhees, New Jersey. He graduated medical school in 1979 and has decades of experience in the field. He is also a member of the Medicare program and accepts medicare assignments.